JW Therapeutics submitted the latest monthly report on securities changes to Hong Kong Exchanges and Clearing Limited on June 6, 2024, reporting changes in the company's shareholding structure as of May 31, 2024. The report shows that the company's statutory/registered share capital remains at 5,000,000,000 shares, with a face value of 0.00001 US dollars, and a total of $50,000, with no increase or decrease this month. However, in terms of share options, according to the company's share option plan, share options have been exercised this month, resulting in a reduction in the number of share options, but the number of share options at the end of this month may still be issued new shares. Specifically, under the first pre-IPO incentive plan adopted...Show More

JW Therapeutics submitted the latest monthly report on securities changes to Hong Kong Exchanges and Clearing Limited on June 6, 2024, reporting changes in the company's shareholding structure as of May 31, 2024. The report shows that the company's statutory/registered share capital remains at 5,000,000,000 shares, with a face value of 0.00001 US dollars, and a total of $50,000, with no increase or decrease this month. However, in terms of share options, according to the company's share option plan, share options have been exercised this month, resulting in a reduction in the number of share options, but the number of share options at the end of this month may still be issued new shares. Specifically, under the first pre-IPO incentive plan adopted on September 4, 2019, and the post-IPO incentive plan adopted on October 14, 2020, share options have been exercised or lapsed, with a total increase of 406,890 ordinary shares this month. The company confirms that all securities issuances have been approved by the board of directors and meet the relevant requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.